958230-19-8

Basic information

• Product Name: 4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE
• Synonyms: 4-Chloro1H-pyrrolo[2,3-b]pyridine-5-carboxaldehyde;4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxaldehyde, 4-Chloro-5-formyl-1H-pyrrolo[2,3-b]pyridine;4-Chloro-7-azaindole-5-carboxaldehyde;4-Chloro-7-azaindole-5-carbaldehyde;1H-Pyrrolo[2,3-b]pyridine-5-carboxaldehyde, 4-chloro-
• CAS NO: 958230-19-8
• Molecular Formula: C₈H₅ClN₂O
• Molecular Weight: 180.59
• Mol File: 958230-19-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.521 g/cm³
• Refractive Index: 1.748
• Storage Temp.: 2-8°C
• PKA: 12.11±0.40(Predicted)
• CAS DataBase Reference: 4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE(958230-19-8)
• EPA Substance Registry System: 4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE(958230-19-8)

Safety Data

• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 958230-19-8(Hazardous Substances Data)

Usage

General Description

4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde is a chemical compound with the molecular formula C8H5ClN2O. It is a heterocyclic compound that consists of a pyrrolopyridine core with a chlorine atom on the fourth position and an aldehyde group on the fifth position. 4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde has potential applications in the field of organic synthesis and medicinal chemistry, where it can be used as an intermediate for the production of various pharmaceuticals. Its unique structure and properties make it a valuable building block for the synthesis of biologically active molecules. However, due to its chemical nature and potential reactivity, proper handling and safety precautions should be followed when working with this compound.

InChI:InChI=1/C8H5ClN2O/c9-7-5(4-12)3-11-8-6(7)1-2-10-8/h1-4H,(H,10,11)

Upstream product

• 55052-28-3 4-chloro-7-azaindole 
• 68-12-2 N,N-dimethyl-formamide 
• 651744-48-8 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1201189-77-6 1-methyl-6-tosyl-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine 
• 1201189-79-8 7-iodo-1-methyl-6-tosyl-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine 
• 1310704-59-6 7-(5-methoxy-1H-indol-3-yl)-1-methyl-6-tosyl-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine 
• 1310704-65-4 2-(5-methoxy-3-(1-methyl-6-tosyl-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridin-7-yl)-1H-indol-1-yl)-N,N-dimethylacetamide 
• 1310704-53-0 tert-butyl 5-methoxy-3-(1-methyl-6-tosyl-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridin-7-yl)-1H-indole-1-carboxylate 
• 1032815-08-9 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR

To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK , IKK , JNK2 2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR , PKA, PKB , PKD2, Rsk1, SAPK2 , SAPK2 , SAPK3, SGK, Tie2 and TrkB kinases.